BD
BDRX.US Biodexa Pharmaceticals
- Market cap
- USD 1.26M
- P/E
- 0.0x
- P/B
- 0.05x
- ROE
- -78.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is BDRX.US undervalued?
Graham numberThe Graham number of Biodexa Pharmaceticals cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Biodexa Pharmaceticals fundamental analysis
No fundamental analysis for Biodexa Pharmaceticals yet.
Biodexa Pharmaceticals stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Biodexa Pharmaceticals
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in…
Full company profileBiodexa Pharmaceticals financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Biodexa Pharmaceticals annual financial statements (GBP; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.32M | 989K | 1.94M | 674K | 343K | 578K | 699K | 381K | 0.00 | 0.00 | - |
| Gross Profit | -6.41M | -7.34M | -7.42M | -7.17M | -5.73M | -4.08M | -4.41M | -3.69M | -5.44M | -185K | -322K |
| Operating Income | -9.65M | -11.8M | -11.8M | -11.3M | -23.0M | -7.00M | -8.93M | -8.01M | -9.20M | -8.27M | -19.0M |
| EBITDA | -5.30M | -10.6M | -10.7M | -9.54M | -22.2M | -5.66M | -8.09M | -7.16M | -8.95M | -8.08M | -18.7M |
| Net Income | -6.16M | -11.7M | -10.4M | -10.1M | -22.2M | -5.46M | -7.66M | -7.08M | -5.73M | -6.24M | -7.52M |
| EPS | - | - | - | -10,085,000 | -5,547,250 | -5,460,000 | -3,100 | -45 | -2.31 | -0.23 | -0.40 |
| Balance Sheet | |||||||||||
| Total Assets | 56.7M | 49.2M | 20.4M | 30.9M | 9.82M | 12.9M | 5.53M | 10.5M | 14.8M | 18.1M | 12.6M |
| Total Liabilities | 11.0M | 14.5M | 3.52M | 11.3M | 3.10M | 2.46M | 2.36M | 5.86M | 6.46M | 6.76M | 3.09M |
| Shareholders' Equity | 45.7M | 34.7M | 16.9M | 19.6M | 6.72M | 10.5M | 3.16M | 4.68M | 8.32M | 11.4M | 9.55M |
| Cash & Short-term Investments | 17.6M | 13.2M | 2.34M | 10.9M | 7.55M | 10.1M | 2.84M | 5.97M | 1.67M | 8.52M | 3.21M |
| Total Debt | 2.16M | 6.55M | 1.25M | 6.08M | 260K | 766K | 624K | 464K | 727K | 60.9K | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -13.1M | -13.0M | -13.5M | -6.49M | -9.30M | -6.01M | -7.05M | -6.83M | -12.3M | -5.39M | -18.5M |
| Capital Expenditure | 1.35M | 707K | 244K | 319K | 209K | 320K | 62.0K | 263K | 774K | 1.96K | 28.6K |
| Free Cash Flow | -14.4M | -13.7M | -13.7M | -6.81M | -9.51M | -6.33M | -7.11M | -7.09M | -13.0M | -5.40M | -18.5M |
| Ratios | |||||||||||
| ROE | -13.5% | -33.8% | -61.3% | -51.6% | -330.3% | -52.2% | -242.1% | -151.3% | -68.8% | -54.8% | -78.7% |
| ROA | -10.9% | -23.8% | -50.7% | -32.6% | -226.0% | -42.3% | -138.6% | -67.2% | -38.8% | -34.4% | -59.4% |
| Net Profit Margin | -465.7% | -1,183.5% | -535.0% | -1,496.3% | -6,469.1% | -944.6% | -1,095.3% | -1,858.0% | - | - | - |
| Debt to Equity | 0.05x | 0.19x | 0.07x | 0.31x | 0.04x | 0.07x | 0.20x | 0.10x | 0.09x | 0.01x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Biodexa Pharmaceticals dividends
Biodexa Pharmaceticals has not paid dividends in the last 9 fiscal years.
Last stock split: 1:8 on Oct 26, 2026.
Who owns Biodexa Pharmaceticals
- Insiders 0.00%
- Institutions 0.71%
- Public & others 99.29%
- Shares outstanding 524K
- Free float 83.8K
Top institutions holding BDRX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Armistice Capital, LLC | 14.8K | 0.67% | -24.07% | Jun 2026 |
| GAMMA Investing LLC | 1.20K | 0.05% | 0.00% | Jun 2026 |
| Allied Private Wealth LLC | 489.00 | 0.02% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 29.00 | 0.00% | -3.33% | Jun 2026 |
| UBS Group AG | 25.00 | 0.00% | 0.00% | Jun 2026 |
| Hilton Head Capital Partners, LLC | 6.00 | 0.00% | 0.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 5.00 | 0.00% | 0.00% | Jun 2026 |
| Rhumbline Advisers | 3.00 | 0.00% | -25.00% | Jun 2026 |
| Sabby Management LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
Biodexa Pharmaceticals company profile
- Company name
- Biodexa Pharmaceticals
- Ticker
- BDRX.US
- ISIN
- GB00BNGF1L75
- Exchange
- USA Stocks
- Listed since
- Dec 7, 2015
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 11
- Fiscal year end
- December
- Address
- 1 Caspian Point, Cardiff, United Kingdom, CF10 4DQ
- Phone
- 44 29 2048 0180
- Website
- biodexapharma.com
About Biodexa Pharmaceticals
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTX240, for the treatment of gastrointestinal stromal tumors. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, nanotechnology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours; and MidaCore, a gold nanoparticle used for targeting sites of disease. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Biodexa Pharmaceticals management
7- Mr. Stephen Anthony StampCEO & Director · born 1961
- Ms. Fiona Mary SharpCompany Secretary, CFO & Director · born 1968
- Dr. Daniel Palmer MBA, Ph.D.Chief Science Officer
- Mr. Steve EllulChief Business Officer
- Dr. Gary A. Shangold CPI, FACOG, M.D.Chief Medical Officer · born 1954
- Mr. Jim KostkaVice President & Head of US Clinical Operations
- Ms. Noreen BhattiVice President of Clinical Operations